adenoviru
vector
encod
mous
interferon
alpha
subtyp
evalu
efficaci
lethal
cowpox
brighton
strain
vaccinia
wr
strain
viru
respiratori
system
infect
mice
two
rout
administr
use
nasal
sinu
pulmonari
compar
differ
efficaci
sinc
prefer
treatment
human
would
rel
small
volum
deliv
intranas
lower
respiratori
infect
lri
upper
respiratori
infect
uri
system
infect
induc
intranas
intranas
intraperiton
viru
challeng
respect
treatment
given
prophylact
either
h
short
term
longterm
prior
viru
challeng
singl
nasal
sinu
treatment
pfumous
protect
mice
vacciniainduc
lri
mortal
compar
publish
studi
pulmonari
deliv
system
vaccinia
infect
respond
significantli
better
nasal
sinu
deliv
pulmonari
treatment
cowpox
lri
infect
respond
treatment
dose
weakli
protect
cowpox
uri
infect
equal
treatabl
nasal
sinu
pulmonari
deliv
pfumous
doserespons
prophylaxi
given
one
time
prior
initi
vaccinia
viru
lri
infect
protect
pfumous
improv
lung
hemorrhag
score
lung
weight
evid
decreas
liver
lung
spleen
viru
titer
thu
abl
treat
differ
vaccinia
cowpox
viru
infect
use
nasal
sinu
pulmonari
treatment
regimen
support
develop
human
citat
smee
df
wong
mh
hurst
bl
enni
j
turner
jd
effect
nasal
pulmonari
deliv
treatment
adenoviru
vector
interferon
respiratori
system
infect
mice
caus
cowpox
vaccinia
virus
plo
one
previou
public
report
adenoviru
vector
mous
interferon
administ
intranas
capabl
protect
mice
infect
vaccinia
wr
strain
viru
infect
model
use
viru
inoculum
induc
primarili
lower
respiratori
infect
lri
also
lesssever
upper
respiratori
infect
uri
sinc
inadminist
liquid
must
pass
snout
way
lung
dose
pfu
mous
administ
lung
volum
h
prior
viru
challeng
protect
mice
death
report
describ
give
singl
dose
day
week
prior
infect
surviv
outcom
result
prior
studi
left
number
unansw
question
util
benefit
mice
might
relat
treatment
human
human
interferon
form
vector
first
question
pertain
treatment
volum
given
mice
treatment
volum
mous
shown
deliv
much
dose
lung
scale
human
base
bodi
weight
would
excess
prefer
treatment
volum
human
small
comfort
receiv
deliv
via
intranas
deliveri
devic
deliv
nasal
mucosa
second
question
relat
type
infect
treatabl
primarili
look
one
viru
model
vaccinia
viru
lri
induc
viru
inocul
develop
infect
model
cowpox
vaccinia
virus
healthi
immunocompet
mice
system
infect
produc
intraperiton
infect
viru
primarili
lri
uri
infect
develop
use
either
larg
small
infect
volum
model
use
address
efficaci
treat
variou
type
infect
caus
cowpox
vaccinia
virus
well
determin
whether
chang
deliveri
nasal
sinu
versu
lung
affect
efficaci
drug
protect
challeng
agent
final
question
rais
previou
studi
pertain
long
act
prophylact
effect
singl
pfumous
dose
given
day
prior
vaccinia
viru
challeng
provid
remark
protect
lower
dose
assess
model
need
test
determin
extend
protect
vector
given
week
infect
indic
previous
needlefre
singl
dose
drug
capabl
achiev
steadyst
method
deliv
interferon
would
maxim
therapeut
benefit
ifn
minim
bolusinduc
toxic
addit
deliveri
adenoviru
vector
bypass
preexist
immun
vector
alreadi
shown
efficaci
mice
infect
figur
effect
treatment
cidofovir
surviv
bodi
weight
chang
b
vaccinia
viru
lower
respiratori
infect
initi
viru
inocul
mice
intranas
treatment
pfu
mous
given
one
time
hour
prior
viru
exposur
cidofovir
mgkgday
administ
ip
day
two
day
hour
infect
figur
show
mean
valu
sem
treat
anim
per
group
placebo
start
experi
compar
placebo
virus
ebola
western
equin
enceph
viru
venezuelan
equin
enceph
viru
sar
human
form
also
activ
hamster
use
treat
yellow
fever
viru
infect
arenaviru
infect
bunyaviru
infect
guinea
pig
infect
ebola
viru
success
treat
combin
vaccin
plu
although
antivir
drug
develop
orthopoxviru
infect
variola
monkeypox
bioterror
agent
human
appear
hold
promis
prophylact
earli
treatment
agent
experi
present
elucid
abil
deliv
nasal
sinu
lung
combat
differ
form
poxviru
infect
experi
conduct
accord
protocol
approv
institut
anim
care
use
committe
utah
state
univers
work
perform
biosafeti
level
area
aaalacaccredit
laboratori
anim
research
center
utah
state
univers
accord
nation
institut
health
guid
care
use
laboratori
anim
individu
involv
work
infect
anim
cell
receiv
prior
vaccin
standard
smallpox
vaccin
femal
balbc
mice
charl
river
lab
wilmington
weigh
approxim
g
time
first
treatment
use
studi
mice
receiv
extend
prophylaxi
week
prior
infect
weigh
g
time
requir
slightli
higher
viru
challeng
dose
lethal
indic
quarantin
period
initi
receipt
anim
randomli
assign
cage
adenoviru
vector
mous
interferon
alpha
prepar
robert
fitzhenri
vector
laboratori
mcmaster
univers
hamilton
canada
method
prepar
describ
previous
briefli
mous
interferon
alpha
gene
subtyp
clone
replic
defici
vector
delet
gene
amplifi
cell
purifi
cesium
chlorid
gradient
centrifug
stock
solut
store
thaw
ice
dilut
salin
appropri
dose
immedi
prior
singl
administr
gilead
scienc
foster
citi
ca
provid
posit
control
compound
cidofovir
vaccinia
viru
wr
strain
purchas
american
type
cultur
collect
atcc
manassa
va
cowpox
viru
brighton
strain
obtain
john
huggin
ft
detrick
frederick
md
cowpox
viru
contain
syncytium
form
figur
effect
treatment
surviv
bodi
weight
chang
b
cowpox
viru
lower
respiratori
infect
initi
viru
inocul
mice
intranas
treatment
pfumous
given
one
time
hour
prior
viru
exposur
cidofovir
mgkgday
administ
day
day
start
hour
viru
challeng
figur
show
mean
valu
sem
treat
anim
per
group
placebo
normal
control
mice
uninfect
untreat
start
experi
compar
placebo
sf
variant
isol
describ
previous
use
studi
virus
propag
african
green
monkey
kidney
cell
atcc
mice
anesthet
ketaminexylazin
mgkg
intraperiton
ip
inject
treatment
infect
ip
infect
requir
anesthesia
amount
infect
viru
pfumous
achiev
complet
lethal
vari
viru
type
infect
rout
infect
volum
follow
vaccinia
ip
vaccinia
cowpox
cowpox
longterm
prophylaxi
studi
perform
use
age
mice
requir
vaccinia
viru
challeng
dose
figur
show
mean
valu
sem
treat
anim
per
group
placebo
normal
control
mice
uninfect
untreat
start
experi
compar
placebo
treatment
vaccinia
cowpox
viru
infect
plo
one
wwwplosoneorg
pfumous
caus
complet
mortal
administ
nasal
sinu
lung
h
prior
vaccinia
viru
exposur
shortterm
prophylaxi
day
prior
infect
long
term
prophylaxi
placebotr
mice
given
salin
rout
anim
weigh
everi
day
start
day
infect
period
mice
cidofovir
treat
group
placebo
per
experi
longterm
prophylaxi
studi
separ
anim
mice
per
group
maintain
determin
tissu
viru
titer
lung
hemorrhag
score
lung
weight
mice
sacrif
remov
tissu
day
infect
lung
given
hemorrhag
score
color
chang
pink
plum
occur
region
lung
rather
gradual
entir
lung
rang
normal
entir
lung
affect
lung
spleen
liver
snout
weigh
prior
homogen
releas
infecti
viru
titrat
homogen
soft
tissu
perform
ml
cell
cultur
medium
use
stomach
snout
ground
ml
medium
use
steril
mortar
pestl
sampl
serial
dilut
increment
plaqu
titrat
micropl
vero
cell
plaqu
stain
three
day
crystal
violet
buffer
formalin
follow
count
plaqu
aid
light
box
plaqu
number
convert
pfu
per
gram
infect
tissu
initi
survivor
number
compar
mantelcox
logrank
test
statist
signific
found
pairwis
analys
perform
use
gehanbreslowwilcoxon
test
differ
tissu
viru
titer
lung
weight
statist
analyz
tukeykram
multipl
comparison
test
lung
hemorrhag
score
analyz
twotail
mannwhitney
utest
analys
perform
use
instath
previous
report
high
volum
treatment
effect
vaccinia
viru
infect
initi
viru
infect
volum
viru
infect
method
caus
lung
infect
lri
sinu
infect
uri
viru
dissemin
tissu
liver
spleen
lower
well
figur
nasal
sinu
treatment
volum
test
efficaci
sinc
volum
would
repres
scale
human
dose
compar
purpos
one
dose
deliv
lung
volum
ip
cidofovir
also
evalu
two
higher
dose
protect
mice
group
death
cidofovir
figur
pfumous
deliv
either
via
nasal
sinu
lung
prevent
mortal
howev
sever
weight
loss
encount
anim
treat
nasal
sinu
deliv
drug
figur
weight
regain
day
deliv
via
lung
pfumous
protect
weight
loss
well
nasal
deliv
dose
cidofovir
vaccinia
viru
system
infect
initi
ip
viru
challeng
effect
manag
prophylact
liver
lung
spleen
major
target
infect
deposit
primarili
either
sinus
volum
lung
volum
would
gener
interferon
ultim
need
reach
liver
organ
protect
complet
protect
afford
dose
administ
nasal
sinu
figur
lower
dose
provid
partial
protect
dose
deliv
lung
less
protect
surviv
dose
deliv
nasal
sinu
surviv
differ
twotail
fisher
exact
test
thu
nasal
sinu
deliv
effect
treat
system
infect
suggest
interferon
produc
express
gene
product
interferon
better
distribut
produc
nose
point
research
orthopoxviru
famili
use
treat
vaccinia
viru
infect
mice
sinc
cowpox
vaccinia
virus
relat
vaccinia
treatabl
could
assum
also
effect
cowpox
viru
infect
investig
administ
lung
cowpox
viru
infect
similar
report
vaccinia
viru
infect
see
also
figur
high
degre
protect
seen
pfu
dose
much
less
pfu
dose
figur
cidofovir
complet
protect
slight
bodi
weight
loss
infect
seen
dose
cidofovir
figur
lower
dose
could
prevent
sever
infectioninduc
weight
loss
comparison
degre
protect
afford
pulmonari
deliv
dose
vaccinia
figur
cowpox
figur
virus
suggest
cowpox
viru
infect
difficult
treat
found
syncytium
form
strain
cowpox
viru
low
volum
inoculum
work
well
caus
lethal
upper
respiratori
tract
infect
mice
minim
lri
involv
report
uri
treat
deliv
nasal
sinu
ml
lung
ml
small
volum
would
concentr
vector
site
infect
wherea
larg
volum
would
deposit
vector
diffus
lung
lung
interferon
produc
would
circul
upper
respiratori
tract
order
exert
benefici
effect
pass
sinus
en
rout
lung
would
vector
deposit
sinus
much
lower
amount
concentr
result
infect
enlighten
dose
pfumous
provid
partial
protect
death
figur
dose
ineffect
nearli
equival
protect
afford
dose
pfu
administ
via
nasal
sinu
lung
result
suggest
upper
respiratori
tract
infect
difficult
treat
even
concentr
amount
administ
local
previous
demonstr
singl
high
pfumous
dose
administ
week
prior
viru
exposur
highli
protect
vaccinia
viru
infect
mice
determin
effect
lower
dose
extend
prophylact
window
administ
day
prior
viru
challeng
three
differ
dose
one
effect
dose
one
day
prior
infect
comparison
figur
surprisingli
even
dose
given
day
preinfect
protect
anim
death
howev
sever
weight
loss
seen
group
wherea
higher
dosag
group
larg
protect
weight
loss
due
infect
figur
paramet
measur
day
postinfect
experi
figur
lung
weight
lung
hemorrhag
score
significantli
less
anim
compar
placebo
figur
respect
liver
viru
titer
nearli
complet
suppress
except
one
liver
anim
treat
unit
figur
highest
level
viru
detect
lung
anim
figur
treatment
dose
reduc
level
significantli
compar
placebo
dose
given
day
preinfect
least
effect
might
expect
bodi
weight
loss
data
figur
dose
administ
day
preinfect
show
compar
viru
titer
reduct
dose
given
day
prior
infect
remark
multipl
statist
comparison
dose
administ
day
preinfect
significantli
differ
less
treatment
snout
viru
titer
significantli
reduc
treatment
figur
may
explain
incomplet
efficaci
achiev
upper
respiratori
tract
infect
figur
final
spleen
viru
titer
undetect
anim
treat
either
day
day
viru
challeng
figur
studi
singl
dose
administ
mice
via
ml
nasal
sinu
lung
combat
differ
manifest
cowpox
vaccinia
viru
infect
includ
primarili
upper
respiratori
primarili
lower
respiratori
system
infect
purpos
evalu
nasal
sinu
deliveri
experi
better
model
prefer
method
treatment
human
infect
volum
mous
would
overwhelm
scale
amount
appropri
human
thu
want
determin
whether
posit
result
report
first
public
influenc
high
treatment
volum
found
present
set
experi
effect
administ
low
volum
nasal
sinu
potenc
vector
deliv
low
volum
rel
high
volum
depend
viru
infect
model
vaccinia
viru
lri
deliv
nasal
sinu
requir
higher
dose
deliv
lung
order
protect
equal
bodi
weight
loss
infect
figur
convers
vaccinia
viru
system
infect
deliv
via
nasal
sinu
clearli
superior
lung
dose
figur
cowpox
viru
uri
differ
rout
administr
appear
equival
efficaci
figur
first
report
report
activ
cowpox
viru
infect
mice
comparison
result
treatment
viru
vaccinia
viru
treatment
suggest
cowpox
viru
infect
difficult
treat
requir
higher
dose
efficaci
also
observ
cowpox
uri
partial
impact
highest
dose
figur
regardless
whether
compound
administ
concentr
form
target
upper
respiratori
tract
dilut
form
target
lower
respiratori
tract
equival
protect
seen
nasal
sinu
pulmonari
treatment
indic
amount
interferon
site
infect
may
import
factor
rather
well
sinus
mount
antivir
respons
although
precis
relev
cowpox
instruct
fact
vaccinia
viral
titer
snout
mice
diminish
treatment
figur
suggest
efficaci
interferon
sinus
lower
tissu
eg
liver
spleen
see
figur
report
also
provid
addit
enlighten
observ
made
previous
remark
long
prophylact
effect
vaccinia
viru
infect
earlier
shown
high
dose
vector
administ
day
week
prior
infect
afford
high
degre
protect
death
evalu
lower
dose
found
protect
anim
death
although
lower
dose
could
protect
excess
weight
loss
figur
also
demonstr
fact
dose
administ
week
preinfect
provid
similar
degre
viral
titer
reduct
capac
dose
administ
day
viru
exposur
figur
addit
lung
weight
lung
hemorrhag
score
mice
similarli
improv
figur
point
remark
long
act
effect
vaccinia
viru
infect
mice
perform
similar
cowpox
viru
infect
extens
pretreat
know
compound
similarli
effect
report
anim
prophylact
protect
nearli
far
day
infect
unrel
virus
sar
coronavirusinfect
mice
yellow
fever
virusinfect
hamster
point
extend
prophylaxi
appear
exist
absenc
measur
serum
interferon
level
know
adenoviru
vector
still
present
snout
treat
mice
day
exposur
unpublish
interferon
present
low
level
may
activ
immunolog
cascad
protect
anim
infect
induc
long
last
antivir
state
antivir
gene
multipl
pathway
identifi
cell
play
virusinhibitori
role
depend
upon
viru
plan
measur
gene
stimul
safeti
studi
look
correl
antivir
protect
set
experi
provid
evid
util
treat
viru
infect
even
lower
dose
lower
treatment
volum
akin
treat
human
use
may
serv
mean
quickli
provid
signific
protect
first
respond
medic
chain
personnel
confront
deliber
releas
variola
monkeypox
viru
environ
mention
treat
varieti
unrel
viru
infect
mani
import
biodefens
public
health
